Integrity Capital Management (HK)’s Clarus Therapeutics Holdings, Inc. Warrants CRXTW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-69,724
Closed -$20K 388
2021
Q4
$20K Buy
+69,724
New +$35.6K 0.06% 294

Other funds holding CRXTW

Integrity Capital Management (HK)'s CRXTW Position: Q1 2022 in Review

Integrity Capital Management (HK) sold out of Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) in Q1 2022, closing a stake of 69,724 shares — an estimated $20K sold.

Integrity Capital Management (HK) first reported a position in CRXTW in Q4 2021 and held it in 1 quarter. The position peaked at $20K in Q4 2021. 16 funds tracked by Wall St. Rank hold CRXTW as of Q1 2022.

  • Integrity Capital Management (HK) reported no remaining Clarus Therapeutics Holdings, Inc. Warrants position as of Q1 2022 after selling out during the quarter.
  • Integrity Capital Management (HK) sold 69,724 Clarus Therapeutics Holdings, Inc. Warrants shares in Q1 2022, an estimated $20K.
  • Integrity Capital Management (HK) first reported a position in Clarus Therapeutics Holdings, Inc. Warrants in Q4 2021 and held it in 1 quarter.
  • Integrity Capital Management (HK)'s Clarus Therapeutics Holdings, Inc. Warrants position peaked at $20K in Q4 2021.
  • 16 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Warrants as of Q1 2022.

Based on Integrity Capital Management (HK)'s 13F filing for Q1 2022, filed 26 Apr 2022.